These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25218042)

  • 1. Repurposing of sodium channel antagonists as potential new anti-myotonic drugs.
    Matthews E; Hanna MG
    Exp Neurol; 2014 Nov; 261():812-5. PubMed ID: 25218042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
    Desaphy JF; Carbonara R; Costanza T; Conte Camerino D
    Exp Neurol; 2014 May; 255(100):96-102. PubMed ID: 24613829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.
    Stunnenberg BC; Raaphorst J; Groenewoud HM; Statland JM; Griggs RC; Woertman W; Stegeman DF; Timmermans J; Trivedi J; Matthews E; Saris CGJ; Schouwenberg BJ; Drost G; van Engelen BGM; van der Wilt GJ
    JAMA; 2018 Dec; 320(22):2344-2353. PubMed ID: 30535218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia.
    Desaphy JF; Costanza T; Carbonara R; Conte Camerino D
    Neuropharmacology; 2013 Feb; 65():21-7. PubMed ID: 23000075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues.
    Catalano A; Franchini C; Carocci A
    Curr Med Chem; 2021; 28(8):1535-1548. PubMed ID: 32364065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
    Andersen G; Hedermann G; Witting N; Duno M; Andersen H; Vissing J
    Brain; 2017 Sep; 140(9):2295-2305. PubMed ID: 29050397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockers of Skeletal Muscle Na
    De Bellis M; Boccanegra B; Cerchiara AG; Imbrici P; De Luca A
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.
    De Bellis M; Carbonara R; Roussel J; Farinato A; Massari A; Pierno S; Muraglia M; Corbo F; Franchini C; Carratù MR; De Luca A; Conte Camerino D; Desaphy JF
    Neuropharmacology; 2017 Feb; 113(Pt A):206-216. PubMed ID: 27743929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of myotonia with antiarrhythmic drugs.
    Kwieciński H; Ryniewicz B; Ostrzycki A
    Acta Neurol Scand; 1992 Oct; 86(4):371-5. PubMed ID: 1455983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of mexiletine versus placebo in patients with myotonia: a systematic review and meta-analysis.
    Elettreby AM; Elnaga AAA; Alsaied MA; Ewis DK; Sharkawy AM; Fareed R; Alderbi GM
    Neurol Sci; 2024 Aug; 45(8):3989-4001. PubMed ID: 38403671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia.
    D'Mello S; Shum L
    Eur J Hosp Pharm; 2016 Nov; 23(6):359-363. PubMed ID: 31156883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker.
    Delnavaz Shahr A; Nasuhi Pur F
    Iran J Pharm Res; 2019; 18(3):1351-1357. PubMed ID: 32641945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
    Logigian EL; Martens WB; Moxley RT; McDermott MP; Dilek N; Wiegner AW; Pearson AT; Barbieri CA; Annis CL; Thornton CA; Moxley RT
    Neurology; 2010 May; 74(18):1441-8. PubMed ID: 20439846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs.
    Carocci A; Catalano A; Bruno C; Lentini G; Franchini C; De Bellis M; De Luca A; Conte Camerino D
    Chirality; 2010 Mar; 22(3):299-307. PubMed ID: 19544349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation.
    Aoike F; Takahashi MP; Sakoda S
    Eur J Pharmacol; 2006 Feb; 532(1-2):24-31. PubMed ID: 16473348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels.
    Duranti A; Franchini C; Lentini G; Loiodice F; Tortorella V; De Luca A; Pierno S; Conte Camerino D
    Eur J Med Chem; 2000 Jan; 35(1):147-56. PubMed ID: 10733611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Na+ channel inactivation by anemone toxin (ATX II) mimics the myotonic state in hyperkalaemic periodic paralysis.
    Cannon SC; Corey DP
    J Physiol; 1993 Jul; 466():501-20. PubMed ID: 8105077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.
    Stunnenberg BC; Woertman W; Raaphorst J; Statland JM; Griggs RC; Timmermans J; Saris CG; Schouwenberg BJ; Groenewoud HM; Stegeman DF; van Engelen BG; Drost G; van der Wilt GJ
    BMC Neurol; 2015 Mar; 15():43. PubMed ID: 25880166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of SCN4A-induced myotonic crisis.
    Ritter DM; Tian C; Broomall E
    Muscle Nerve; 2021 Jun; 63(6):E59-E61. PubMed ID: 33745142
    [No Abstract]   [Full Text] [Related]  

  • 20. [Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine].
    Pouget J; Serratrice G
    Rev Neurol (Paris); 1983; 139(11):665-72. PubMed ID: 6677978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.